Hyderabad: India is a step closer to getting the first naval COVID-19 vaccine.
Clinical phase 3 trials of Bharat Biotech’s COVID-19 nasal vaccine have been completed, and the Hyderabad-based company will soon be submitting its data to Drugs Controller General of India (DCGI) next month.
“We just completed a clinical trial, a data analysis is going on. Next month, we will submit the data to the regulatory agency. If everything is okay, then we will get permission to launch and it will be the world’s first clinically proven nasal COVID-19 vaccine,” Bharat Biotech Chairman and MD Dr Krishna Ella told ANI.
DCGI had granted permission to Bharat Biotech to conduct standalone phase 3 trials in January.
Dr Ella was in Paris as a speaker at Viva Technology 2022, where India was declared country of the year.
“I am glad to say 65 startups from India, under NITI Aayog they all came, showing that technology to a lot of people, what India can do, how India can innovate for the world. They are vibrant because I was a startup in 1997,” Dr Ella said.
